TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22679721

Group type: EXPERIMENTAL
Intervention: Huzhang Tongfeng Granule (HTG), diclofenac sodium extended‐release capsule, Jinhuang Ointment (JO) in the acute stage; Yinlian Tongfeng Granule (YTG) and Benzbromarone Tablet (BT) in the intermission stage.
Number of subjects: 120

Group type: COMPARATOR
Intervention: diclofenac sodium extended‐release capsule in the acute stage; Benzbromarone Tablet (BT) in the intermission stage.
Number of subjects: 120
Study: 20140407

Group type: EXPERIMENTAL
Intervention: Group-based motor training programme once a week for 8 consecutive weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Individual-based motor training programme once a week for 8 consecutive weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Group-based training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Individual-based training
Number of subjects: 23
Study: 17071931

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Mitoxantrone, Chlorambucil, Prednisone (MCP)
Number of subjects: 79
Study: 16267764

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 504
Study: 12015533

Group type: EXPERIMENTAL
Intervention: Smoking at enrollment
Number of subjects: 4589

Group type: COMPARATOR
Intervention: Quit smoking before LMP
Number of subjects: 4589
Study: 9792265

Group type: EXPERIMENTAL
Intervention: Wavelet decomposition analysis
Number of subjects: 246

Group type: COMPARATOR
Intervention: Patients dying non-suddenly
Number of subjects: 246
Study: 8533562

Group type: EXPERIMENTAL
Intervention: SFM (casual sex with foreign males)
Number of subjects: 996
Study: 2403484

Group type: COMPARATOR
Intervention: Ticarcillin‐clavulanate plus vancomycin (TV)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Ceftazidime plus vancomycin (CV)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: All three antibiotics (TCV)
Number of subjects: 535
Study: 31830292

Group type: EXPERIMENTAL
Intervention: Topical citicoline eye drops three times a day for 1 month
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lubricant hyaluronic acid (0.15%) eye drops three times a day for 1 month
Number of subjects: 78
Study: 28071649

Group type: EXPERIMENTAL
Intervention: 3.5‐h sleep duration
Number of subjects: 9

Group type: COMPARATOR
Intervention: 7‐h sleep duration
Number of subjects: 9
Study: 26115112

Group type: EXPERIMENTAL
Intervention: Didactic lecture
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Brainstorming workshop
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (delayed education)
Number of subjects: 496
Study: 23948533

Group type: EXPERIMENTAL
Intervention: Higher perceived drinking peer norms
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Perceived drinking norms
Number of subjects: 193
Study: 21304094

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9978

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 9978
Study: 19801056

Group type: EXPERIMENTAL
Intervention: Arc‐RADs
Number of subjects: 16

Group type: COMPARATOR
Intervention: C‐RADs
Number of subjects: 16
Study: 16954488

Group type: EXPERIMENTAL
Intervention: Educational outreach visits (1 hour)
Number of subjects: 6451

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6451
Study: 15178665

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11430565

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg at 09:00 and 2.5 mg at 14:00)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg at 23:00) with prednisolone (2.5 mg at 14:00)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 14
Study: 9409140

Group type: EXPERIMENTAL
Intervention: 3 months outpatient treatment (experimental group)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 6 months outpatient treatment (experimental group)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (3 months treatment)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (6 months treatment)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 230
Study: 7968645

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptive (30 mcg ethinyl estradiol plus 75 mcg gestodene)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 16
Study: 3115455

Group type: EXPERIMENTAL
Intervention: Computer based system for dietary assessment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary history method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Food tables for nutrient calculation
Number of subjects: 50
Study: 30277890

Group type: EXPERIMENTAL
Intervention: Low tidal volume-airway pressure release ventilation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Volume control
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Day 3 PaO2/FIO2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sedation, vasoactive medications, or occurrence of pneumothorax
Number of subjects: 52
Study: 28350519

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMAs)
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN)
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Other treatments (MISC)
Number of subjects: 1698

Group type: COMPARATOR
Intervention: RBC transfusions only (Control)
Number of subjects: 1698
Study: 26184525

Group type: EXPERIMENTAL
Intervention: Rilonacept (160mg intrabursal injection)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (80mg in 6mL mixture of lidocaine and bupivacaine)
Number of subjects: 33
Study: 22938910

Group type: EXPERIMENTAL
Intervention: Polylens Y10 (1-piece IOL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polylens Y30 (3-piece IOL)
Number of subjects: 40
Study: 21992986

Group type: EXPERIMENTAL
Intervention: Expedited Partner Therapy (EPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Partner Referral (SR)
Number of subjects: 0
Study: 18182977

Group type: EXPERIMENTAL
Intervention: D1 surgery (n=110)
Number of subjects: 221

Group type: COMPARATOR
Intervention: D3 surgery (n=111)
Number of subjects: 221

Group type: COMPARATOR
Intervention: D1 and D3 patients
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Total gastrectomy, advanced cancer, hemipancreaticosplenectomy
Number of subjects: 221
Study: 17004900

Group type: EXPERIMENTAL
Intervention: Soy protein (25 g protein, four times a week for 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Whey protein (control)
Number of subjects: 17
Study: 14581272

Group type: EXPERIMENTAL
Intervention: Docetaxel (36 mg/m²)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m²)
Number of subjects: 71
Study: 10812870

Group type: EXPERIMENTAL
Intervention: Evidence-based decision making
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experience-based decision making
Number of subjects: 0
Study: 8702052

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg kg‐1 in 250 ml 5% dextrose i.v. over 30 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo in 250 ml 5% dextrose i.v. over 30 min
Number of subjects: 30
Study: 1731546

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (100 mg IV) followed 1 min later by propofol (2 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol (2 mg/kg IV)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 2% lidocaine administered after a tourniquet inflated to 50 mm Hg for 1 min
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline placebo with tourniquet
Number of subjects: 82
Study: 6748177

Group type: EXPERIMENTAL
Intervention: 50 mg of zinc sulfate daily for eight weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29961562

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 27554507

Group type: EXPERIMENTAL
Intervention: Structured preoperative phone call 2 to 3 weeks prior to surgery (Group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional consent process by consultant surgeon (Group A)
Number of subjects: 43
Study: 26278425

Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin daily from preoperative day 7 to postoperative day 28
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23616503

Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) diet (150 g/d)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Refined grain (RG) diet
Number of subjects: 17
Study: 20173541

Group type: EXPERIMENTAL
Intervention: Endoscopic choroid plexus cauterization (ECPC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 17
Study: 18219250

Group type: EXPERIMENTAL
Intervention: proxy-patient perspective
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: proxy-proxy perspective
Number of subjects: 224
Study: 16966684

Group type: EXPERIMENTAL
Intervention: Metabolic responders (defined as a decrease in metabolic activity of the primary tumor by more than 35%)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metabolic nonresponders
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metabolic response
Number of subjects: 65
Study: 15273016

Group type: EXPERIMENTAL
Intervention: Visual exposure to women (in person or within photographs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10826509

Group type: COMPARATOR
Intervention: 5 kb deletion in failing hearts (CHF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 7.4 kb deletion in failing hearts (CHF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5 kb deletion in ventricles of older persons (> 35 yrs)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 7.4 kb deletion in ventricles of older persons (> 35 yrs)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: mtDNA amount in left ventricle
Number of subjects: 33
Study: 9104663

Group type: EXPERIMENTAL
Intervention: Intravenous PCA
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intramuscular injections (IM)
Number of subjects: 73
Study: 8240927

Group type: EXPERIMENTAL
Intervention: (R,S)-atenolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (R)-atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (S)-atenolol 50 mg
Number of subjects: 12
Study: 2946975

Group type: EXPERIMENTAL
Intervention: Maprotiline 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indalpine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indalpine 50 mg
Number of subjects: 0
Study: 31640317

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (CAF) - 25 ml of mint syrup with 1.2% of CAF, equivalent to 300 mg of CAF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA) - 25 ml of mint syrup without CAF
Number of subjects: 10
Study: 30202945

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1709
Study: 26329293

Group type: EXPERIMENTAL
Intervention: Prednisone (PRD) 40 mg/m²/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 10 mg/kg/day with PRD
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal bone marrow)
Number of subjects: 32
Study: 24331154

Group type: EXPERIMENTAL
Intervention: Tecemotide (806 μg lipopeptide) administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Number of subjects: 829
Study: 23016882

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 256

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 256
Study: 20414680

Group type: EXPERIMENTAL
Intervention: Precut technique
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 6
Study: 18056501

Group type: EXPERIMENTAL
Intervention: Universal Spine System
Number of subjects: 129

Group type: COMPARATOR
Intervention: Moss Miami system
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Surgeon satisfaction with Universal Spine System
Number of subjects: 129
Study: 16120857

Group type: EXPERIMENTAL
Intervention: Intensive belatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less-intensive belatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belatacept (both regimens)
Number of subjects: 0
Study: 11777260

Group type: EXPERIMENTAL
Intervention: 15 months of once‐weekly topical amorolfine lacquer + 6 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 15 months of once‐weekly topical amorolfine lacquer + 12 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147

Group type: COMPARATOR
Intervention: 12 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147
Study: 9108791

Group type: EXPERIMENTAL
Intervention: 4G allele and homozygous 4G4G genotype associated with high PAI‐1 levels in centenarians
Number of subjects: 254

Group type: COMPARATOR
Intervention: Comparison group (young, healthy individuals)
Number of subjects: 254
Study: 8510064

Group type: EXPERIMENTAL
Intervention: Conservative treatments including drug therapy and counselling
Number of subjects: 0
Study: 3479012

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 71
Study: 28890996

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study: 27356786

Group type: EXPERIMENTAL
Intervention: Observation group (vertebral artery tortuosity)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vertebral artery tortuosity)
Number of subjects: 60
Study: 24164961

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21503940

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg daily
Number of subjects: 191
Study: 18690353

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose followed by 75 mg daily) and Aspirin (75-325 mg daily for at least six months)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin
Number of subjects: 3719
Study: 16491004

Group type: EXPERIMENTAL
Intervention: Combined phototherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fiberoptic Wallaby
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fiberoptic Biliblanket
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 140
Study: 12930422

Group type: EXPERIMENTAL
Intervention: Orchidectomy plus lycopene (OL)
Number of subjects: 54
Study: 10698138

Group type: EXPERIMENTAL
Intervention: Reduction attempts (hyperpronation and supination/flexion)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Radiographs for patients who failed reduction attempts
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nonclassic history for mechanism of injury
Number of subjects: 136
Study: 9302132

Group type: EXPERIMENTAL
Intervention: Alprostadil injections 3 times per week for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation without any erectogenic treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alprostadil injections
Number of subjects: 30
Study: 8377686

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin (100 mg daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 3118730

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 29954336

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 300
Study: 27504845

Group type: COMPARATOR
Intervention: Oral health counseling
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oral health counseling and fluoride varnish
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Control (no preventive intervention)
Number of subjects: 300
Study: 24518002

Group type: EXPERIMENTAL
Intervention: High Five intervention
Number of subjects: 445
Study: 24316936

Group type: EXPERIMENTAL
Intervention: PD-WEBB training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20008946

Group type: COMPARATOR
Intervention: Fluoxetine monotherapy (20 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Fluoxetine (20 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Venlafaxine (225 mg/day titrated in 14 days)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Bupropion (150 mg/day)
Number of subjects: 105
Study: 18833043

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) concentration of 1.6%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) concentration of 2%
Number of subjects: 100
Study: 21050763

Group type: EXPERIMENTAL
Intervention: Hip muscle fatigue
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ankle muscle fatigue
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no fatigue)
Number of subjects: 28
Study: 16186422

Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin pretreatment (1200 mg PO)
Number of subjects: 100
Study: 11900105

Group type: EXPERIMENTAL
Intervention: Strategic regulation of grain size in memory reporting
Number of subjects: 0
Study: 9587726

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (averaging mode for the previous 6 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (averaging mode for the previous 3 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous thermodilution technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent bolus technique
Number of subjects: 24
Study: 8057708

Group type: EXPERIMENTAL
Intervention: Electrostimulated acupuncture (EA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Superficial needle position (SNP) acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (SNP)
Number of subjects: 24
Study: 2459540

Group type: EXPERIMENTAL
Intervention: Quinapril (10 to 40 mg twice daily, increased every 4 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29663982

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine mini lozenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg nicotine mini lozenge
Number of subjects: 0
Study: 27059056

Group type: EXPERIMENTAL
Intervention: Hemoadsorption (HA) using CytoSorb™
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 25691502

Group type: EXPERIMENTAL
Intervention: 0.05% ascending breath alcohol concentration (BrAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.08% peak breath alcohol concentration (BrAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% descending breath alcohol concentration (BrAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compensatory Tracking Task, Digit Symbol Substitution Test, Brief Stop Signal Task, Inspection Time Task
Number of subjects: 0
Study: 24308890

Group type: EXPERIMENTAL
Intervention: Telephone-based obesity prevention programme (multiple computer aided telephone counselling interviews)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Telephone-based obesity prevention programme
Number of subjects: 303
Study: 20496731

Group type: EXPERIMENTAL
Intervention: Acupoint sticking of Wuzhuyu (Evodia Rutaecarpa) at Neiguan (PC 6) and Xinshu (BL 15), once each day for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Xinbao pills, 3 pills each time, thrice each day for 4 weeks.
Number of subjects: 60
Study: 17653617

Group type: EXPERIMENTAL
Intervention: Soft hip protectors
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Hard hip protectors
Number of subjects: 1236
Study: 16612259

Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cyclosporine continuation (n = 12)
Number of subjects: 24
Study: 12759717

Group type: EXPERIMENTAL
Intervention: Atropine infusion (0.15 microg/kg/min continuously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isoprenaline infusion (3.5‐35 ng/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Terbutaline infusion (25‐150 ng/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Adrenaline infusion (20‐160 ng/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bicycle exercise in supine position
Number of subjects: 6
Study: 10793322

Group type: EXPERIMENTAL
Intervention: Donepezil (initially 3 mg per day, increased to 5, 7, and 10 mg per day as needed)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 133